Discounted Cash Flow
Royalty Pharma Plc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $1.8b | $-140.1m | $-140.1m | -7.8% | — |
| 2019 | $1.8b (1.1%) | $-112.9m (19.4%) | $-112.9m (19.4%) | -6.2% (20.3%) | — |
| 2020 | $2.1b (17.0%) | $-726.9m (-543.9%) | $2.0b (1902.4%) | -34.3% (-450.5%) | $-1.94 |
| 2021 | $2.3b (7.9%) | $621.5m (185.5%) | $2.0b (-0.8%) | 27.1% (179.3%) | $1.50 (177.4%) |
| 2022 | $2.2b (-2.3%) | $187.2m (-69.9%) | $187.2m (-90.7%) | 8.4% (-69.2%) | $0.43 (-71.5%) |
| 2023 | $2.4b (5.2%) | $565.3m (201.9%) | $3.0b (1495.8%) | 24.0% (186.9%) | $1.26 (195.4%) |
| 2024 | $2.3b (-3.9%) | $471.8m (-16.5%) | $2.8b (-7.3%) | 20.8% (-13.2%) | $1.05 (-16.6%) |
| 2025 | $2.4b (5.1%) | $553.2m (17.3%) | $2.5b (-10.1%) | 23.3% (11.6%) | $1.29 (22.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.